KSHV/HHV8, the eighth human herpesvirus, was discovered in applicant's laboratory in 1993. It is associated with three human proliferative diseases ranging from hyperplastic proliferation to neoplasia: Castleman's disease, Kaposi's sarcoma, and primary effusion lymphoma (PEL). These disorders are rarely expressed in the general population, but are common among KSHV seropositive individuals who are immunocompromised, particularly AIDS patients. During the past grant period, the investigators sequenced the viral genome, and discovered and characterized a number of viral genes likely to play a role in KSHV pathogenesis. Their studies have concentrated on latent viral genes expressed in tumor cells that are likely to modify host cell regulatory pathways. By mapping whole genome expression and determining protein expression patterns, they have identified specific viral genes likely to play roles in cell proliferation and prevention of apoptosis in situ. Recently, they have found a latently expressed gene, which is not a component of the previously described major latency transcript locus, LT1 and LT2 encompassing v-cyclin (0RF72) and LANA1 (0RF73). This 1704 bp spliced gene encodes a protein designated latency-associated nuclear antigen (LANA) 2, which is localized to the nucleus and is expressed in all KSHV-infected PEL-derived cells. LANA2 has structural similarities to the IRF4 transcriptional factor present in B cells. This renewal seeks to characterize this latent protein and investigate its potential role in KSHV-related diseases. The four specific aims of this proposal are: 1) to extend the characterization of LANA2 concentrating on the in vivo expression of the protein in KSHV-associated disease tissues, 2) to extend their preliminary studies demonstrating LANA2-mediated upregulation of the CD23 B cell activation antigen, which is also induced by Epstein-Barr virus infection, 3) to identify protein-protein interactions between LANA2 and host cell proteins involved in CD23 transcriptional regulation, and 4) to investigate the potential role of this latent viral gene on cell cycle regulation, apoptosis and in vitro cell transformation. These studies may provide critical insights into the biological role of CD23 signaling in lymphomagenesis and in herpesvirus infection of B cells. Characterization of LANA2 may also contribute to an important future diagnostic and therapeutic target for KSHV infection

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA067391-10
Application #
6658141
Study Section
Special Emphasis Panel (ZRG1-AARR-4 (01))
Program Officer
Read-Connole, Elizabeth Lee
Project Start
1995-04-01
Project End
2005-01-31
Budget Start
2003-02-01
Budget End
2004-01-31
Support Year
10
Fiscal Year
2003
Total Cost
$335,719
Indirect Cost
Name
University of Pittsburgh
Department
Pathology
Type
Schools of Medicine
DUNS #
004514360
City
Pittsburgh
State
PA
Country
United States
Zip Code
15213
Feng, Huichen; Taylor, Jennifer L; Benos, Panayiotis V et al. (2007) Human transcriptome subtraction by using short sequence tags to search for tumor viruses in conjunctival carcinoma. J Virol 81:11332-40
Taylor, Jennifer L; Bennett, Heather N; Snyder, Beth A et al. (2005) Transcriptional analysis of latent and inducible Kaposi's sarcoma-associated herpesvirus transcripts in the K4 to K7 region. J Virol 79:15099-106
Laney, A Scott; De Marco, Teresa; Peters, Jonathan S et al. (2005) Kaposi sarcoma-associated herpesvirus and primary and secondary pulmonary hypertension. Chest 127:762-7
Moore, Patrick S; Chang, Yuan (2003) Kaposi's sarcoma-associated herpesvirus immunoevasion and tumorigenesis: two sides of the same coin? Annu Rev Microbiol 57:609-39
Rivas, C; Thlick, A E; Parravicini, C et al. (2001) Kaposi's sarcoma-associated herpesvirus LANA2 is a B-cell-specific latent viral protein that inhibits p53. J Virol 75:429-38
Parravicini, C; Chandran, B; Corbellino, M et al. (2000) Differential viral protein expression in Kaposi's sarcoma-associated herpesvirus-infected diseases: Kaposi's sarcoma, primary effusion lymphoma, and multicentric Castleman's disease. Am J Pathol 156:743-9
Iscovich, J; Fischbein, A; Fisher-Fischbein, J et al. (2000) Seroprevalence of Kaposi's sarcoma-associated herpesvirus in healthy adults in Israel. Anticancer Res 20:2119-22
Sarid, R; Wiezorek, J S; Moore, P S et al. (1999) Characterization and cell cycle regulation of the major Kaposi's sarcoma-associated herpesvirus (human herpesvirus 8) latent genes and their promoter. J Virol 73:1438-46
Jayachandra, S; Low, K G; Thlick, A E et al. (1999) Three unrelated viral transforming proteins (vIRF, EBNA2, and E1A) induce the MYC oncogene through the interferon-responsive PRF element by using different transcription coadaptors. Proc Natl Acad Sci U S A 96:11566-71
Olsen, S J; Tarte, K; Sherman, W et al. (1998) Evidence against KSHV infection in the pathogenesis of multiple myeloma. Virus Res 57:197-202

Showing the most recent 10 out of 24 publications